Company: SWAGW
Filing Date: 2025-04-14
Form Type: 10-K
Source: 0001213900-25-031596
Chunk: 54

Company: Stran & Company, Inc.
Filing Date: 2025-04-14
Form: 10-K
Item: Item 1
Chunk 54
---
, 2025, the Company filed its Quarterly Report on Form 10-Q for the period ended September 30, 2024. As a result,
the Company has regained compliance with the Filing Rule. On February 20, 2025, the Company received a written notification from the Staff
notifying the Company that for the last 11 consecutive business days, from February 4, 2025 to February 19, 2025, the closing bid price
of the Company’s common stock has been at $1.00 per share or greater. Accordingly, the Company regained compliance with the Bid
Price Rule. In addition, the Company will schedule its annual meeting for 2024 and 2025 to take place in the second quarter of 2025. Upon
the conclusion of such annual meeting, the Company will regain compliance with the Annual Meeting Rule.

Although we have regained compliance with the
Filings Rule and the Bid Price Rule, no assurance can be provided that we will regain compliance with the Annual Meeting Rule or otherwise
remain in compliance with the Nasdaq Listing Rules. In addition, our board of directors may determine that the cost of maintaining our
listing on a national securities exchange outweighs the benefits of such listing. A delisting of our common stock and publicly-traded
warrants from Nasdaq may materially impair our stockholders’ ability to buy and sell our common stock and publicly-traded warrants
and could have an adverse effect on the market price of, and the efficiency of the trading market for, our common stock and publicly-traded
warrants. The delisting of our common stock and publicly-traded warrants could also significantly impair our ability to raise capital
and the value of your investment.

Our publicly-traded warrants may not have
any value.

Our publicly-traded warrants are exercisable for
five years from the date of initial issuance and currently have an exercise price of $4.81375 per share. There can be no assurance that
the market price of our shares of common stock will equal or exceed the exercise price of the publicly-traded warrants. In the event that
the stock price of our shares of common stock does not exceed the exercise price of the publicly-traded warrants during the period when
the publicly-traded warrants are held and exercisable, the publicly-traded warrants may not have any value to their holders.

33

Holders of publicly-traded warrants have
no rights as stockholders until such holders exercise their publicly-traded warrants and acquire our